IP Library › Granted Patent US 12,479,883
Granted Patent B2
US 12,479,883 · App. 17/517,531 · Granted Nov 25, 2025

Methods of reducing the enzymatic hydrolysis activity rate in a composition obtained from a purification platform

Inventors: Michael Leiss (Schlehdorf, DE); Christian Meyer (Starnberg, DE); Alexandra Thomas Morris (Pacifica, CA); Bernhard Spensberger (Eberfing, DE); Yinges Yigzaw (San Ramon, CA); Franziska Edelmann (Wolfratshausen, DE); Roberto Falkenstein (Munich, DE); Tobias Graf (Penzberg, DE); Jie Gu (Thousand Oaks, CA); Jeevan Prabhakar (San Francisco, CA)
Assignees: Genentech, Inc.; Hoffmann-La Roche Inc.
C07K1/22A61K39/39591B01D15/327B01D15/362B01D15/3809B01D15/3847B01D39/1623B01D39/2068B01D61/145C07K1/165C07K1/20C07K1/34C07K1/36B01D61/147B01D2239/0618B01D2315/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,479,883
App. No.
17/517,531
Granted
Nov 25, 2025
Kind
B2
Abstract

The present disclosure provides purification platforms comprising a depth filter step and/or a hydrophobic interaction chromatography (HIC) step. Also disclosed herein are methods of using the purification platforms described herein and compositions obtained therefrom, such as pharmaceutical compositions.

Claims (28)

1 . A method of reducing an enzymatic hydrolysis activity rate of a composition obtained from a purification platform, the method comprising subjecting a sample to the purification platform comprising, in order:

(a) a capture step comprising processing via affinity chromatography; and

(b) a purification step comprising processing via a chromatography selected from the group consisting of a HIC, a cation exchange chromatography, and a multimodal chromatography,

wherein the purification platform further comprises one or more depth filtration steps,

wherein the one or more depth filtration steps are performed at any one or more of: prior to the capture step; after the capture step; or after the capture step and prior to the purification step,

wherein each depth filtration step comprises processing via a depth filter, and

wherein the depth filter comprises materials selected from the group consisting of:

(i) a silica filter aid and a polyacrylic fiber pulp; and

(ii) cellulose fibers, diatomaceous earth, and perlite,

wherein the depth filter comprising the cellulose fibers, diatomaceous earth, and perlite comprises two layers, wherein each layer comprises a cellular filter matrix impregnated with a filter aid comprising one or more of diatomaceous earth or perlite, and wherein each layer further comprises a resin binder,

thereby reducing the enzymatic hydrolysis activity rate of the composition as compared to purification of the sample using the same purification platform without the one or more depth filtration steps.

2 . The method of claim 1 , wherein the relative reduction of the enzymatic hydrolysis activity rate of the composition, as compared to purification of the sample using the same purification platform without the depth filtration step, is at least about 20%.

3 . The method of claim 1 , wherein the level of one or more hydrolytic enzymes in the composition obtained from the purification platform is reduced as compared to purification of the sample using the same purification platform without the one or more depth filtration steps, and wherein the relative reduction of the level of one or more hydrolytic enzymes in the composition, as compared to purification of the sample using the same purification platform without the depth filtration step, is at least about 20%.

4 . The method of claim 1 , wherein the degradation of a polysorbate in the composition obtained from the purification platform is reduced as compared to purification of the sample using the same purification platform without the one or more depth filtration steps, and wherein the relative reduction of degradation of the polysorbate in the composition, as compared to purification of the sample using the same purification platform without the depth filtration step, is at least about 5%.

5 . The method of claim 1 , wherein the depth filter is selected based on the pH of the solution entering the depth filter, and wherein the depth filter comprising the silica filter aid and the polyacrylic fiber pulp is selected when the solution entering the depth filter is about 5 to about 6.5.

6 . The method of claim 1 , wherein the HIC is a phenyl SEPHAROSE® fast flow chromatography.

7 . The method of claim 1 , wherein the cation exchange chromatography is POROS®50HS.

8 . The method of claim 1 , wherein the purification platform further comprises a second depth filtration step comprising processing via the depth filter comprising the silica filter aid and the polyacrylic fiber pulp, and wherein the second depth filtration step occurs after the capture step and prior to the purification step.

9 . The method of claim 1 , wherein the multimodal chromatography is Capto Adhere.

10 . The method of claim 1 , wherein the purification platform further comprises a second depth filtration step comprising processing via a depth filter comprising a hydrogel Q-functionalized non-woven media and a multi-zone microporous membrane, and wherein the second depth filtration step occurs after the capture step and prior to the purification step.

11 . The method of claim 1 , wherein the purification platform is for purification of a target from the sample, wherein the sample comprises the target and one or more host cell impurities, and wherein the host cell impurity is a host cell protein.

12 . The method of claim 1 , wherein the purification platform further comprises a virus inactivation step, wherein the virus inactivation step is performed after the capture step.

13 . The method of claim 12 , wherein the one or more depth filtration steps are performed after the virus inactivation step.

14 . The method of claim 1 , wherein the purification platform further comprises an ultrafiltration/diafiltration (UFDF) step, and wherein the UFDF step is performed after the purification step.

15 . The method of claim 1 , further comprising determining the enzymatic hydrolysis activity rate of the composition.

16 . The method of claim 1 , further comprising determining the level of one or more hydrolytic enzymes in the composition.

17 . The method of claim 1 , wherein the sample comprises one or more host cell proteins, wherein one of the one or more host cell proteins is a hydrolytic enzyme, and wherein the hydrolytic enzyme is a lipase, an esterase, a thioesterase, a phospholipase, or a ceramidase.

18 . The method of claim 1 , wherein the affinity chromatography is a protein A chromatography from FcXL affinity chromatography or MABSELECT SURE™.

Continuity (4)
Continuation PCTUS2020031164 · May 1, 2020
Provisional Application 62961609 · Jan 15, 2020
Provisional Application 62843261 · May 3, 2019
Related Publication 20220194980A1 · Jun 23, 2022
References Cited (142)
US 4676980A · Segal · 1987 [cited by applicant]
US 4816567A · Cabilly · 1989 [cited by applicant]
US 4882013A · Turner et al. · 1989 [cited by applicant]
US 5591828A · Bosslet · 1997 [cited by applicant]
US 5731168A · Carter · 1998 [cited by applicant]
US 9249182B2 · Herigstad · 2016 [cited by applicant]
US 10342876B2 · Bak et al. · 2019 [cited by applicant]
US 11518781B2 · Koehnlein · 2022 [cited by applicant]
US 20080069820A1 · Fuh · 2008 [cited by applicant]
US 20110207196A1 · Koehler · 2011 [cited by applicant]
US 20130090389A1 · Vitins et al. · 2013 [cited by applicant]
US 20140010820A1 · Wang et al. · 2014 [cited by applicant]
US 20140309403A1 · Brown et al. · 2014 [cited by applicant]
US 20160176921A1 · Rajendran · 2016 [cited by examiner]
US 20160272674A1 · Althouse et al. · 2016 [cited by applicant]
US 20170073396A1 · Bataille · 2017 [cited by applicant]
US 20170189536A1 · Connolly · 2017 [cited by examiner]
US 20180360856A1 · Holmes et al. · 2018 [cited by applicant]
US 20180369258A1 · Holmes et al. · 2018 [cited by applicant]
US 20220135620A1 · Seay et al. · 2022 [cited by applicant]
US 20220194980A1 · Leiss et al. · 2022 [cited by applicant]
US 20230047100A1 · Arcadu et al. · 2023 [cited by applicant]
US 20230049176A1 · Pompiati · 2023 [cited by applicant]
EP 0404097A2 · 1990 [cited by applicant]
WO 199311161A1 · 1993 [cited by applicant]
WO 199850431A2 · 1998 [cited by applicant]
WO 199850431A3 · 1999 [cited by applicant]
WO 200177342A1 · 2001 [cited by applicant]
WO 2003100080A2 · 2003 [cited by applicant]
WO 2006044532A1 · 2006 [cited by applicant]
WO 2008024715A2 · 2008 [cited by applicant]
WO 2008024715A3 · 2008 [cited by applicant]
WO 2009080251A1 · 2009 [cited by applicant]
WO 2009080252A1 · 2009 [cited by applicant]
WO 2009080253A1 · 2009 [cited by applicant]
WO 2009089004A1 · 2009 [cited by applicant]
WO 2010048192A2 · 2010 [cited by applicant]
WO 2010048192A3 · 2010 [cited by applicant]
WO 2010112193A1 · 2010 [cited by applicant]
WO 2010115589A1 · 2010 [cited by applicant]
WO 2010136172A1 · 2010 [cited by applicant]
WO 2010145792A1 · 2010 [cited by applicant]
WO 2011034605A2 · 2011 [cited by applicant]
WO 2011034605A3 · 2011 [cited by applicant]
WO 2011150110A1 · 2011 [cited by applicant]
WO 2013009491A2 · 2013 [cited by applicant]
WO 2013026831A1 · 2013 [cited by applicant]
WO 2013028330A2 · 2013 [cited by applicant]
WO 2013028330A3 · 2013 [cited by applicant]
WO 2013177115A2 · 2013 [cited by applicant]
WO 2014004281A1 · 2014 [cited by applicant]
WO 2013177115A3 · 2014 [cited by applicant]
WO 2015023468A1 · 2015 [cited by applicant]
WO 2015031899A1 · 2015 [cited by applicant]
WO 2015077605A1 · 2015 [cited by applicant]
WO 2015095539A1 · 2015 [cited by applicant]
WO 2015150447A1 · 2015 [cited by applicant]
WO 2015198320A1 · 2015 [cited by applicant]
WO 2016016299A1 · 2016 [cited by applicant]
WO 2016106291A1 · 2016 [cited by applicant]
WO 2016172485A2 · 2016 [cited by applicant]
WO 2016172485A3 · 2016 [cited by applicant]
WO 2017027861A1 · 2017 [cited by applicant]
WO 2017031476A2 · 2017 [cited by applicant]
WO 2017095062A1 · 2017 [cited by applicant]
WO 2017218977A2 · 2017 [cited by applicant]
WO 2017218977A3 · 2018 [cited by applicant]
WO 2018035025A1 · 2018 [cited by applicant]
WO 2018170488A1 · 2018 [cited by applicant]
WO 2018200430A1 · 2018 [cited by applicant]
WO 2019191416A1 · 2019 [cited by applicant]
WO 2020006266A1 · 2020 [cited by applicant]
WO 2020023566A1 · 2020 [cited by applicant]
WO 2020159838A1 · 2020 [cited by applicant]
WO 2020200980A1 · 2020 [cited by applicant]
WO 2021144422A1 · 2021 [cited by applicant]
WO 2022094116A1 · 2022 [cited by applicant]
Arnold, “Fluid Purification Using Charge-Modified Depth Filtration Media”, 2005, BioProcess International, p. 44-49. (Year: 2005). [cited by examiner]
Al-Lazikani, B. et al. (1997). “Standard Conformations for the Canonical Structures of Immunoglobulins,” J. Mol. Biol. 273:927-948. [cited by applicant]
Charlton, H.R. (Jan. 1, 1999). “Characterisation of a Generic Monoclorial Antibody Harvesting System for Adsorption of DNA by Depth Filters and Various Membranes,” Bioseparation 8:281-291, 27 pages. [cited by applicant]
Chiu, J. et al. (May 2017). “Knockout of a Difficult-To-Remove CHO Host Cell Protein, Lipoprotein Lipase, For Improved Polysorbate Stability in Monoclonal Antibody Formulations: CHO LP,L Knockout and Polysorbate Degrada… [cited by applicant]
Chothia, C. et al. (1987). “Canonical Structures for the Hypervariable Regions of Immunoglobulins,” J. Mol. Biol. 196:901-917. [cited by applicant]
Chothia, C. et al. (Dec. 1989). “Conformations of Immunoglobulin Hypervariable Regions,” Nature 342(6252):877-883. [cited by applicant]
Chothia, C. et al. (Dec. 5, 1985). “Domain Association in Immunoglobulin Molecules. The Packing of Variable Domains,” J. Mol. Biol. 186(3):651-663. [cited by applicant]
Hall, T. et al. (May 2006, e-pub. Apr. 5, 2016). “Polysorbates 20 and 80 Degradation by Group XV Lysosomal Phospholipase A2 Isomer XI in, Monoclonal Antibody Formulations,” Journal of Pharmaceutical Sciences 105(5):1633… [cited by applicant]
Hollinger, P. et al. (Jul. 1993). “Diabodies: Small Bivalent and Bispecific Antibody Fragments,” Proc. Natl. Acad. Sci. USA 90:6444-6448. [cited by applicant]
International Preliminary Report on Patentability, issued Nov. 2, 2021, for PCT Application No. PCT/US2020/031164, filed May 1, 2020, 9 pages. [cited by applicant]
International Search Report and Written Opinion, mailed Jul. 17, 2020, for PCT Application No. PCT/US2020/031164, filed May 1, 2020, 17 pages. [cited by applicant]
Invitation to Pay Additional Fees, mailed Feb. 10, 2022, for PCT Application No. PCT/US2021/057100, filed Oct. 28, 2021, 21 pages. [cited by applicant]
Jones, P. et al. (May 29, 1986). “Replacing the Complementarity-Determining Regions in a Human Antibody With Those From a Mouse,” Nature 321:522-525. [cited by applicant]
Kabat, E.A. et al. (1991). Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD. TOC, 21 pages. [cited by applicant]
Liu, H. et al. (Sep./Oct. 2010). “Recovery and Purification Process Development for Monoclonal Antibody Production,” mAbs 2(5): 480-499. [cited by applicant]
Marichal-Gallardo, P.A. et al. (2012, e-pub. Jun. 26, 2012). “State-Of-The-Art in Downstream Processing of Monoclonal Antibodies: Process Trends in Design and Validation,” Biotechnology Progress 28(4):899-916. [cited by applicant]
Morrison, S.C. et al. (Nov. 1984). “Chimeric Human Antibody Molecules: Mouse Antigen-Binding Domains With Human Constant Region Domains,” Proc. Natl. Acad. Sci. USA 81:6851-6855. [cited by applicant]
Nguyen, H.C. et al. (May 11, 2018). “Improved HCP Reduction Using a New, All-Synthetic Depth Filtration Media Within an Antibody Purification Process,” Biotechnology Journal 14(1):1700771, 11 pages. [cited by applicant]
Plückthun, A. (1994). “Antibodies from [cited by applicant]
Presta, L.G. (1992). “Antibody Engineering,” Current Opinion in Structural Biology, 2:593-596. [cited by applicant]
Riechmann, L. et al. (Mar. 24, 1988). “Reshaping Human Antibodies for Therapy,” Nature 332:323-327. [cited by applicant]
Yigzaw, Y. et al. (2006, e-pub. Jan. 1, 2006). “Exploitation of the Adsorptive Properties of Depth, Filters for Host Cell Protein Removal During Monoclonal Antibody Purification,” Biotechnology Progress 22(1):288-296. [cited by applicant]
Yu, D. et al. (Jun. 11, 2019). “Control of Antibody High and Low Molecular Weight Species by Depth Filtration-Based Cell Culture Harvesting,” Biotechnology and Bioengineering 116(10):2610-2620. [cited by applicant]
Zhou, J.X. et al. (Oct. 1, 2008). “Implementation of Advanced Technologies in Commercial Monoclonal Antibody Production,” Biotechnology Journal 3(9-10):1185-1200. [cited by applicant]
Atwell, S. et al. (1997). “Stable Heterodimers From Remodeling the Domain Interface of a Homodimer Using a Phage Display Library,” J. Mol. Biol. 270 (1):26-35. [cited by applicant]
Brennan, M. et al. (Jul. 5, 1985). “Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G1 Fragments,” Science 229:81-83. [cited by applicant]
Chadd, H.E. et al. (2001). “Therapeutic Antibody Expression Technology,” Curr. Opin. Biotechnol 12:188-194. [cited by applicant]
Giese, G. et al. (2018, e-pub. Nov. 29, 2017). “Bispecific Antibody Process Development: Assembly and Purification of Knob and Hole Bispecific Antibodies,” Biotechnol. Prog. 34(2):397-404. Abstract Only, 3 pages. [cited by applicant]
Gruber, M. et al. (1994). “Efficient Tumor Cell Lysis Mediated by a Bispecific Single Chain Antibody Expressed in [cited by applicant]
Holliger, P. et al. (Sep. 2005, e-pub. Sep. 7, 2005) “Engineered Antibody Fragments and the Rise of Single Domains,” Nat. Biotechnol. 23(9):1126-1136. [cited by applicant]
International Preliminary Report on Patentability, issued Jul. 19, 2022, for PCT Application No. PCT/EP2021/050809, filed Jan. 15, 2021, 8 pages. [cited by applicant]
International Search Report and Written Opinion, mailed Mar. 31, 2022 for PCT Application No. PCT/US2021/057100, filed Oct. 28, 2021, 24 pages. [cited by applicant]
Klein, C. et al. (Jun. 10, 2016, e-pub. Jul. 11, 2016). “The Use of CrossMab Technology for the Generation of Bi- and Multispecific Antibodies,” MABS 8(6):1010-1020. [cited by applicant]
Kostelny, S.A. et al. (Mar. 1, 1992). “Formation of a Bispecific Antibody by the Use of Leucine Zippers,” J. Immunol. 148(5):1547-1553. [cited by applicant]
Merchant, A. M. et al. (Jul. 1998). “An Efficient Route to Human Bispecific IgG,” Nature Biotechnology 16:677-681. [cited by applicant]
Milstein, C. et al. (Oct. 6, 1983). “Hybrid Hybridomas and Their Use in Immunohistochemistry,” Nature 305:537-540. [cited by applicant]
Onur, A. et al. (Sep. 12, 2018). “Multi-Layer Filters: Adsorption and Filtration Mechanisms for Improved Separation,” Frontiers in Chemistry 6(417):1-11. [cited by applicant]
Ridgway, J.B.B. et al. (1996). “Knobs-Into-Holes' Engineering of Antibody CH3 Domains for Heavy Chain Heterodimerization,” Protein Engineering 9(7):617-621. [cited by applicant]
Schaefer, W. et al. (Jul. 5, 2011, e-pub. Jun. 20, 2011). “Immunoglobulin Domain Crossover as a Generic Approach for the Production of Bispecific IgG Antibodies,” Proc. Natl. Acad. Sci. U.S.A. 108(27):11187-11192. [cited by applicant]
Singh, N. et al. (2017, e-pub. Jan. 12, 2017). “Development of Adsorptive Hybrid Filters to Enable Two-Step Purification of Biologics,” MABS 9(2):350-364. [cited by applicant]
Spiess, C. et al. (2015, e-pub. Jan. 27, 2015). “Alternative Molecular Formats and Therapeutic Applications for Bispecific Antibodies,” Mol. Immunol. 67:95-106. [cited by applicant]
Tutt, A. et al. (Jul. 1, 1991). “Trispecific F(ab′)3 Derivatives that use Cooperative Signaling via the TCR/CD3 Complex and CD2 to Activate and Redirect Resting Cytotoxic T Cells,” J. Immunol. 147(1):60-69. [cited by applicant]
U.S. Appl. No. 17/767,842, Davies et al, filed Apr. 8, 2022. (Copy not submitted herewith pursuant to the waiver of 37 C.F.R. § 1.98(a)(2)(iii) issued by the Office on Sep. 21, 2004). [cited by applicant]
Van Dijk, M.A. et al. (Aug. 2001). “Human Antibodies as Next Generation Therapeutics,” Curr. Opin. Che. Biology 5(4):368-374. [cited by applicant]
Amara, J. et al. (Sep. 2016). “Novel Synthetic Adsorptive Depth Filter Media for CHO Harvest Clarification,” Merck Poster, 1 page. [cited by applicant]
Anonymous (Jun. 2018). Millstak+® HC Pro Data Sheet, Merck, 5 pages. [cited by applicant]
European Office Action, dated May 17, 2023, for European Patent Application No. 21701079.2, 6 pages. [cited by applicant]
International Preliminary Report on Patentability, issued May 2, 2023, for PCT Application No. PCT/US2021/057100, filed Oct. 28, 2021, 14 pages. [cited by applicant]
Li, Y. (2017, e-pub. Apr. 13, 2017). “Effective Strategies for Host Cell Protein Clearance in Downstream Processing of Monoclonal Antibodies and Fc-Fusion Proteins,” Protein Expression and Purification 134:96-103. [cited by applicant]
Lu, C. et al. (Jan./Feb. 2013, e-pub. Dec. 19, 2012). “Characterization of Monoclonal Antibody Size Variants Containing Extra Light Chains,” Mabs 5(1):102-113. [cited by applicant]
Wang, S. et al. (2018, e-pub. Mar. 16, 2018). “Characterization of Product-Related Low Molecular Weight Impurities in Therapeutic Monoclonal Antibodies Using Hydrophilic Interaction Chromatography Coupled with Mass Spec… [cited by applicant]
3M Purification Inc. (Oct. 22, 2020). “Polisher ST Scale-up Capsules: Scale-Up Capsules Installation and Operation Instruction,” 34-8726-1126-3, Datasheet, 82 pages. [cited by applicant]
3M Purification Inc. (Sep. 2018). “Safety Information & Installation and Operation Instructions,” 34-8723-4281-0 Datasheet, 80 pages. [cited by applicant]
Anonymous (Jun. 2020). “Prefilter Selection Guide,” Merck KGaA MK_PG5156EM datasheet, 4 pages. [cited by applicant]
Follman, D.K. et al. (2004). “Factorial Screening of Antibody Purification Processing Using Three Chromatography Steps Without Protein A,” Journal of Chromatography A 1024:79-85. [cited by applicant]
Ghose, S. et al. (2013). “Purification of Monoclonal Antibodies by Hydrophobic Interaction Chromatography Under No-Salt Conditions,” Mabs. 5(5):795-800. [cited by applicant]
Kishore, R.S.K. et al. (Feb. 2011, e-pub Aug. 27, 2010) “Degradation of Polysorbates 20 and 80: Studies on Thermal Autoxidation and Hydrolysis,” Journal of Pharmaceutical Sciences 100(2):721-731. [cited by applicant]
Pall Life Sciences Data Sheet (Sep. 2004). “Pall Mustang S Capsules,” PELEH/02.SH/CS/09.2004 Datasheet, 4 pages. [cited by applicant]
International Search Report and Written Opinion, mailed Mar. 23, 2021, for PCT Application No. PCT/EP2021/050809, filed Jan. 15, 2021, 16 pages. [cited by applicant]
Xu, J. (2011). “Viral and Plasmid Transduction Systems: Methods to Modify Immune Cells for Cancer Immunotherapy,” Nature Biotechnology, 29 pages. [cited by applicant]
GE Healthcare (Nov. 2013). “Instructions 71-7129-00 AF: Phenyl Sepharose High Performance; Butyl Sepharose High Performance,” 16 pages. [cited by applicant]
Tianjin, J. et al. (2018). “Research Progress in Purification Technology of Antibody Drugs in Process of Large-Scale Production,” China Academic Journal 35(10):6-11. English Abstract, 6 pages. [cited by applicant]
Hester, J. et al. (Oct. 2020). “Streamlined Polishing and Viral Clearance: Using a New Hybrid, Biomimetic, Single-Use Anion Exchanger,” BioProcess International 18(10):70-76. [cited by applicant]
Millistak+ ® HC Pro (Sep. 9, 2020). Millipore, With English Translation. 12 pages. [cited by applicant]
Extended European Search Report, dated Jun. 25, 2020, for European Patent Application No. 20151994.9, 9 pages. [cited by applicant]